CYCLOPHARM LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.8 AUD | +2.86% |
|
+2.86% | -6.49% |
| 19/03 | Cyclopharm's Technegas Device Carries Out Imaging of First US Patients | MT |
| 18/03 | Cyclopharm Limited(ASX:CYC) added to S&P/ASX All Ordinaries Index | CI |
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The company returns high margins, thereby supporting business profitability.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company appears highly valued given the size of its balance sheet.
- For the past year, analysts have significantly revised downwards their profit estimates.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -6.49% | 111M | - | ||
| +7.62% | 218B | B | ||
| +6.70% | 183B | B- | ||
| +11.94% | 134B | B- | ||
| +24.60% | 106B | A- | ||
| -1.90% | 61.12B | A- | ||
| +4.81% | 50.89B | B+ | ||
| +11.55% | 51.26B | B+ | ||
| -1.09% | 40.3B | A | ||
| +26.82% | 32.05B | B+ |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
-
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- CYC Stock
- Ratings Cyclopharm Limited
